What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to disclose BeOne Medicines Ltd.'s participation in the J.P. Morgan 39th Annual Healthcare Conference and to provide investors with access to the presentation materials that will be used at the conference.

Where can I find the information BeOne Medicines Ltd. is presenting to investors?

The investor presentation is attached to this 8-K filing as Exhibit 99.1. You should review this exhibit for detailed information about the company's updates and outlook.

When and where is the J.P. Morgan Healthcare Conference taking place?

The J.P. Morgan 39th Annual Healthcare Conference is taking place during the week of January 10, 2021, in San Francisco.

Does this presentation have the same legal implications as a formal SEC filing?

No, the presentation is specifically noted as not being 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, which means it does not automatically subject the company to the liabilities associated with that section, nor is it automatically incorporated into other SEC filings unless expressly stated.

ONC/BEIGF 8-K: Regulation FD

Summary

BeOne Medicines Ltd. (ONC) has filed a Current Report on Form 8-K to disclose its participation in the J.P. Morgan 39th Annual Healthcare Conference. The primary purpose of this filing is to furnish a copy of the company's presentation that will be shared with investors during the conference. This presentation likely contains updates on the company's strategic initiatives, pipeline developments, and financial outlook, providing valuable insights into BeiGene's current trajectory and future prospects.

Key Highlights

1BeOne Medicines Ltd. is participating in the J.P. Morgan 39th Annual Healthcare Conference.
2An investor presentation intended for the conference is attached as Exhibit 99.1.
3The filing incorporates the presentation by reference, making its content available to the public.
4The conference takes place during the week of January 10, 2021, in San Francisco.
5This event serves as a platform for BeiGene to communicate key information to the investment community.
6The presentation is not deemed 'filed' under Section 18 of the Exchange Act, limiting certain liabilities.

BeOne Medicines Ltd. 8-K Report, Regulation FD Disclosure (Jan 11, 2021)

Summary

Key Highlights

Frequently Asked Questions